CNS PHARMACEUTICALS INC (CNSP) Stock Price, Quote, News and Overview
NASDAQ:CNSP - Nasdaq - US18978H4092 - Common Stock - Currency: USD
CNSP Quote, Performance and Key Statistics
1.09
+0.05 (+4.81%)
The current stock price of CNSP is 1.09 USD. In the past month the price decreased by -17.42%. In the past year, price decreased by -99.8%.
CNSP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 68.04 | 838.54B | ||
| JNJ | JOHNSON & JOHNSON | 15.38 | 372.51B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 17.94 | 275.58B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.12 | 221.49B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.76 | 215.69B | ||
| MRK | MERCK & CO. INC. | 10.62 | 208.21B | ||
| PFE | PFIZER INC | 7.37 | 129.99B | ||
| SNY | SANOFI-ADR | 13.38 | 128.08B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.53 | 97.47B | ||
| GSK | GSK PLC-SPON ADR | 8.6 | 75.84B | ||
| ZTS | ZOETIS INC | 25.92 | 68.46B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.98 | 47.30B |
Related stock screener links
About CNSP
Company Profile
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 3 full-time employees. The company went IPO on 2019-11-08. The firm's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The firm is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.
Company Info
CNS PHARMACEUTICALS INC
2100 West Loop S Ste 900
Houston TEXAS 77027 US
CEO: John Climaco
Employees: 4
Company Website: https://cnspharma.com/
Investor Relations: https://ir.cnspharma.com/
Phone: 18009469185
CNS PHARMACEUTICALS INC / CNSP FAQ
What is the stock price of CNS PHARMACEUTICALS INC today?
The current stock price of CNSP is 1.09 USD. The price increased by 4.81% in the last trading session.
What is the ticker symbol for CNS PHARMACEUTICALS INC stock?
The exchange symbol of CNS PHARMACEUTICALS INC is CNSP and it is listed on the Nasdaq exchange.
On which exchange is CNSP stock listed?
CNSP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CNS PHARMACEUTICALS INC stock?
8 analysts have analysed CNSP and the average price target is 204 USD. This implies a price increase of 18615.6% is expected in the next year compared to the current price of 1.09. Check the CNS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CNS PHARMACEUTICALS INC worth?
CNS PHARMACEUTICALS INC (CNSP) has a market capitalization of 3.20M USD. This makes CNSP a Nano Cap stock.
How many employees does CNS PHARMACEUTICALS INC have?
CNS PHARMACEUTICALS INC (CNSP) currently has 4 employees.
What are the support and resistance levels for CNS PHARMACEUTICALS INC (CNSP) stock?
CNS PHARMACEUTICALS INC (CNSP) has a resistance level at 1.1. Check the full technical report for a detailed analysis of CNSP support and resistance levels.
Should I buy CNS PHARMACEUTICALS INC (CNSP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CNSP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CNSP, evaluating the profitability, health, valuation and growth aspects
- CNS PHARMACEUTICALS INC (CNSP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CNS PHARMACEUTICALS INC (CNSP) Sales and EPS estimates to see what analysts future expectations are.
- CNS PHARMACEUTICALS INC (CNSP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CNS PHARMACEUTICALS INC (CNSP) Insider and Institutional Ownership to learn about the owners and their transactions.
- CNS PHARMACEUTICALS INC (CNSP) Stock Chart to make your own analysis
- CNS PHARMACEUTICALS INC (CNSP) Latest news and press-releases to stay up to date.
Does CNS PHARMACEUTICALS INC (CNSP) stock pay dividends?
CNSP does not pay a dividend.
When does CNS PHARMACEUTICALS INC (CNSP) report earnings?
CNS PHARMACEUTICALS INC (CNSP) will report earnings on 2025-05-13.
What is the Price/Earnings (PE) ratio of CNS PHARMACEUTICALS INC (CNSP)?
CNS PHARMACEUTICALS INC (CNSP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-810).
What is the Short Interest ratio of CNS PHARMACEUTICALS INC (CNSP) stock?
The outstanding short interest for CNS PHARMACEUTICALS INC (CNSP) is 11.56% of its float. Check the ownership tab for more information on the CNSP short interest.
CNSP Technical Analysis
CNSP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNSP. CNSP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CNSP Financial Highlights
Over the last trailing twelve months CNSP reported a non-GAAP Earnings per Share(EPS) of -810. The EPS increased by 5.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -170.76% | ||
| ROE | -240.55% | ||
| Debt/Equity | 0.05 |
CNSP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CNSP. The Buy consensus is the average rating of analysts ratings from 8 analysts.